Form 4: Ginkgo Bioworks Director Ross Fubini Reports Stock Option and RSU Grants

Director Ross Fubini reports the acquisition of stock options and restricted stock units (RSUs) in Ginkgo Bioworks Holdings, Inc. related to director compensation.

Summary

• Ross Fubini, a director of Ginkgo Bioworks Holdings, Inc., reported the acquisition of stock options and restricted stock units (RSUs) on June 13, 2024.
• The transactions are related to the Non-Employee Director Compensation Program.
• Fubini acquired 1,111,111 stock options with an exercise price of $0.462, valued at $400,000 based on the Black-Scholes model.
• These options vest in equal installments over three years.
• Additionally, Fubini acquired 571,428 stock options with an exercise price of $0.462, valued at $200,000 based on the Black-Scholes model.
• Fubini also acquired 432,900 RSUs, each representing a right to receive one share of Class A Common Stock.
• The vesting date for the RSUs and the additional stock options is the day before the next Annual Meeting of Shareholders, contingent on continued service as a Non-Employee Director.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. It reflects standard compensation practices for a director, aligning their interests with the company's long-term success. There are no indications of negative events or concerns.

Positives

• The grants of stock options and RSUs align director compensation with the long-term performance of the company.
• The vesting schedules incentivize continued service as a Non-Employee Director.

Future Outlook

The vesting of the RSUs and additional stock options is contingent upon the Reporting Person continuing in service as a Non-Employee Director through the date immediately prior to the next Annual Meeting of Shareholders.

Industry Context

This filing is standard practice for reporting changes in beneficial ownership by company insiders, particularly directors, and is common in the biotechnology industry where equity compensation is frequently used.

Comparison to Industry Standards

• Equity compensation for non-employee directors is a common practice across the biotechnology industry.
• Companies like Amyris and Zymergen (before its acquisition) also utilized stock options and RSUs as part of their director compensation packages.
• The Black-Scholes model is a standard method for valuing stock options, ensuring transparency and comparability across different companies.
• The vesting schedules, typically spanning three years, are also in line with industry norms to incentivize long-term commitment.

Stakeholder Impact

• Shareholders may view the equity grants as a way to align director interests with long-term company performance.
• The grants do not have an immediate impact on employees, customers, suppliers, or creditors.

Key Dates